RT Journal Article
SR Electronic
T1 A single dose of SARS-CoV-2 FINLAY-FR-1A dimeric-RBD recombinant vaccine enhances neutralization response in COVID-19 convalescents, with excellent safety profile. A preliminary report of an open-label phase 1 clinical trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.22.21252091
DO 10.1101/2021.02.22.21252091
A1 Chang-Monteagudo, Arturo
A1 Ochoa-Azze, Rolando
A1 Climent-Ruiz, Yanet
A1 Macías-Abraham, Consuelo
A1 Rodríguez-Noda, Laura
A1 Valenzuela-Silva, Carmen
A1 Sánchez-Ramírez, Belinda
A1 Perez-Nicado, Rocmira
A1 González-Mugica, Raúl
A1 Hernández-García, Tays
A1 Orosa-Vázquez, Ivette
A1 Díaz-Hernández, Marianniz
A1 de los A. García-García, María
A1 Jerez-Barceló, Yanet
A1 Triana-Marrero, Yenisey
A1 Ruiz-Villegas, Laura
A1 Rodríguez-Prieto, Luis
A1 Puga-Gómez, Rinaldo
A1 Guerra-Chaviano, Pedro Pablo
A1 Zúñiga-Rosales, Yaíma
A1 Marcheco-Teruel, Beatriz
A1 Rodríguez-Acosta, Mireida
A1 Noa-Romero, Enrique
A1 Enríquez-Puertas, Juliet
A1 Porto-González, Delia
A1 Leon-Monzon, Kalet
A1 Chen, Guan-Wu
A1 Martinez, Luis Herrera
A1 Valdés-Balbín, Yury
A1 García-Rivera, Dagmar
A1 Vérez-Bencomo, Vicente
A1 ,
YR 2021
UL http://medrxiv.org/content/early/2021/03/03/2021.02.22.21252091.abstract
AB We evaluated response to a single dose of the FINLAY-FR-1A recombinant dimeric-RBD base vaccine during a phase I clinical trial with 30 COVID-19 convalescents, to test its capacity for boosting natural immunity. This short report shows: a) an excellent safety profile one month after vaccination for all participants, similar to that previously found during vaccination of naïve individuals; b) a single dose of vaccine induces a >20 fold increase in antibody response one week after vaccination and remarkably 4-fold higher virus neutralization compared to the median obtained for Cuban convalescent serum panel. These preliminary results prompt initiation of a phase II trial in order to establish a general vaccination protocol for convalescents.Competing Interest StatementFinlay Vaccine Institute and Center for Molecular Immunology has filed patent applications relating to use vaccination in individuals with preexisting immunity SARS-CoV-2Clinical TrialIFV/COR/07 RPCE00000349Clinical Protocols https://rpcec.sld.cu/trials/RPCEC00000349 Funding StatementThis work was partially funded by Fondo de Ciencia e Innovacion (FONCI) from the Ministry of Science and Enviroment of Cuba (Project-2020-20)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Independent Ethical Committee for the Study of Human Subjects in the Institute of Hematology and ImmunologyAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will b e available at https://rpcec.sld.cu/trials/RPCEC00000349 or under request to author